Table 4.

Observed responses for patients treated at the 40-µg/kg dose level

	Dose escalation/expansion (40 µg/kg), n (%)		Treatment naive* (40 µg/kg), n (%)
	All treated (N = 18)	Efficacy evaluable† (N = 17)	All treated (N = 27)	Efficacy evaluable† (N = 26)
CR	2 (11)	2 (12)	6 (22)	6 (23)
CRi	3 (17)	3 (18)	9 (33)	9 (35)
mLFS	3 (17)	3 (18)	4 (15)	4 (15)
Resistant disease	9 (50)	9 (53)	7 (26)	7 (27)
CRc rate (CR + CRi)	5 (28)	5 (29)	15 (56)	15 (58)
Blast clearance (CR+ CRi + mLFS)	8 (44)	8 (47)	19 (70)	19 (73)

^*Includes the treatment-naive cohort and 3 patients in the 40 µg/kg–dose-escalation cohort who were treatment naive.

^†Includes all treated patients who had a BM examination and response determination at least once after the first study treatment.